Recognizing and Managing the Side Effects of Androgen Deprivation Therapy

Posted by Alicia K. Morgans, MD, MPH | Apr 2020

Alicia K. Morgans, MD, MPH, presented “Recognizing and Managing the Side Effects of Androgen Deprivation Therapy” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.

How to cite: Morgans, Alicia K. “Recognizing and Managing the Side Effects of Androgen Deprivation Therapy” September 13th, 2019. Accessed Apr 2024. https://grandroundsinurology.com/recognizing-and-managing-the-side-effects-of-androgen-deprivation-therapy/

Recognizing and Managing the Side Effects of Androgen Deprivation Therapy – Summary:

Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the side effects of androgen deprivation therapy (ADT) and how urologists can mitigate them. She observes that up to 40% of non-metastatic prostate cancer patients are treated with ADT, and those patients tend to be older and have more comorbidities. Studies have suggested that comorbidities and advanced age interact with ADT to increase risk of cardiovascular disease and diabetes. ADT is also associated with increased risk of depression, cognitive changes, and possibly dementia, as well as greater frailty in patients. Urologists should be aware of these side effects so that they can assess their patients’ risk and plan accordingly with multidisciplinary teams to reduce mortality and morbidity and improve quality of life.

About The 5th Annual Prostate & Urologic Cancer Symposium:

The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Cross presented this lecture during the 5th iteration of this summit in 2019.

Please click here for further educational content from this conference.

About The Author

Alicia K. Morgans, MD, MPH

Alicia K. Morgans is an Associate Professor of Medicine (Hematology and Oncology) at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine in Chicago, where she provides clinical care and does research in genitourinary malignancies. Dr. Morgans received her MD from the University of Pennsylvania in 2006. She then completed her internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania in 2009, and her fellowship in Hematology-Oncology at the Dana-Farber Cancer Institute in 2012. In 2015, Dr. Morgans received her MPH from Vanderbilt University School of Medicine. Since 2004, her work on a myriad of important uro-oncological topics has been included in such publications as Urology, European Urology, Prostate, and Cancer Medicine. She is also on the Editorial Board of the Journal of Clinical Oncology. Additionally, she is currently leading three active clinical trials.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat